Michael Yee
Stock Analyst at Jefferies
(2.72)
# 1,991
Out of 4,944 analysts
82
Total ratings
40%
Success rate
7.86%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Maintains: Hold | $3.7 → $5 | $4.46 | +12.11% | 4 | Jul 8, 2025 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.62 | +387.73% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $8.52 | +134.74% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $128.93 | +39.61% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $387.77 | +41.84% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $284.98 | +33.34% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $13.22 | +240.39% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $25.66 | +114.34% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $12.53 | +179.33% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $13.95 | +186.74% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $768.57 | -49.91% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.32 | +331.03% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $3.25 | -7.69% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $16.86 | +77.94% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $14.88 | +34.41% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $32.20 | -37.89% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $7.44 | +908.74% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.63 | +1,040.68% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $31.87 | +103.95% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $9.25 | +12,062.16% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.79 | +1,575.98% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $7.54 | +297.88% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $23.91 | +401.88% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $18.85 | +297.88% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $21.95 | +36.67% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $19.20 | +301.04% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $120.02 | - | 3 | Jan 26, 2018 |
CARGO Therapeutics
Jul 8, 2025
Maintains: Hold
Price Target: $3.7 → $5
Current: $4.46
Upside: +12.11%
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.62
Upside: +387.73%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $8.52
Upside: +134.74%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $128.93
Upside: +39.61%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $387.77
Upside: +41.84%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $284.98
Upside: +33.34%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $13.22
Upside: +240.39%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $25.66
Upside: +114.34%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $12.53
Upside: +179.33%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $13.95
Upside: +186.74%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $768.57
Upside: -49.91%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.32
Upside: +331.03%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $3.25
Upside: -7.69%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $16.86
Upside: +77.94%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $14.88
Upside: +34.41%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $32.20
Upside: -37.89%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $7.44
Upside: +908.74%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.63
Upside: +1,040.68%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $31.87
Upside: +103.95%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $9.25
Upside: +12,062.16%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.79
Upside: +1,575.98%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $7.54
Upside: +297.88%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $23.91
Upside: +401.88%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $18.85
Upside: +297.88%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $21.95
Upside: +36.67%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $19.20
Upside: +301.04%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $120.02
Upside: -